It sure would POS.
As I have posted on this before, this is a clear signal to everyone who's targeting ASDs that Neuren are committed to and able to execute on their plans, that they have support from the major research and advocacy groups that have to be involved and that they're clearly well ahead of the Co's in this space.
Another tick for Neuren and we haven't even touched on trials/funding to follow for all other ASDs.
Tony
proactive investors, page-5
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.54 |
Change
-0.490(2.88%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $16.94 | $17.02 | $16.38 | $10.33M | 620.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5061 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.62 | 1284 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |